ATE465986T1 - Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck - Google Patents

Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck

Info

Publication number
ATE465986T1
ATE465986T1 AT06717964T AT06717964T ATE465986T1 AT E465986 T1 ATE465986 T1 AT E465986T1 AT 06717964 T AT06717964 T AT 06717964T AT 06717964 T AT06717964 T AT 06717964T AT E465986 T1 ATE465986 T1 AT E465986T1
Authority
AT
Austria
Prior art keywords
cyclopentanones
treatment
substituted cyclopentanes
eye hypertension
hypertension
Prior art date
Application number
AT06717964T
Other languages
English (en)
Inventor
David Old
Todd Gac
Vinh Ngo
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE465986T1 publication Critical patent/ATE465986T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/74—Unsaturated compounds containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06717964T 2005-01-14 2006-01-10 Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck ATE465986T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64406905P 2005-01-14 2005-01-14
PCT/US2006/000831 WO2006076370A2 (en) 2005-01-14 2006-01-10 Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions

Publications (1)

Publication Number Publication Date
ATE465986T1 true ATE465986T1 (de) 2010-05-15

Family

ID=36678136

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717964T ATE465986T1 (de) 2005-01-14 2006-01-10 Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck

Country Status (19)

Country Link
US (1) US7635716B2 (de)
EP (1) EP1846354B1 (de)
JP (1) JP5060311B2 (de)
KR (1) KR101227808B1 (de)
CN (1) CN101102989B (de)
AR (1) AR052876A1 (de)
AT (1) ATE465986T1 (de)
AU (1) AU2006205029B2 (de)
BR (1) BRPI0605926A2 (de)
CA (1) CA2593661A1 (de)
DE (1) DE602006013945D1 (de)
DK (1) DK1846354T3 (de)
ES (1) ES2343430T3 (de)
IL (1) IL184025A (de)
MX (1) MX2007008188A (de)
NZ (1) NZ555945A (de)
TW (1) TWI379696B (de)
WO (1) WO2006076370A2 (de)
ZA (1) ZA200704739B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8039507B2 (en) 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
JP2009541340A (ja) * 2006-06-20 2009-11-26 アラーガン インコーポレイテッド 治療用化合物
WO2008008701A2 (en) * 2006-07-10 2008-01-17 Allergan, Inc. Substituted cyclopentane derivatives as therapeutic agents
US20080015219A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
US7507817B2 (en) 2006-11-17 2009-03-24 Allergan, Inc. Prostaglandin prodrugs
CA2675632A1 (en) * 2007-01-22 2008-07-31 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
DK2170345T3 (da) * 2007-07-03 2013-05-13 Allergan Inc Terapeutiske substituerede cyclopentaner til reduktion af intraokulært tryk
BRPI0819707A2 (pt) * 2007-11-29 2015-06-16 Allergan Inc Ciclopentanos substituídas tendo atividade de prostaglandina
BRPI0911543A2 (pt) * 2008-04-24 2015-10-13 Allergan Inc arilciclopentenos substituídos como agentes terapêuticos
EP4046628A1 (de) 2013-10-31 2022-08-24 Allergan, Inc. Prostamidhaltige intraokulare implantate und verfahren zur verwendung davon
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9981938B2 (en) 2014-05-12 2018-05-29 Allergan, Inc. Quaternary ammonium alkyl esters as stable prodrugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980700A (en) 1971-10-07 1976-09-14 G. D. Searle & Co. Prostaglandin intermediates and optically active isomers thereof
SE436037B (sv) * 1976-04-30 1984-11-05 Roussel Uclaf Sett att framstella nya 11-desoxi-prostaglandin-f?712-derivat
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
DK0951282T3 (da) 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
ES2246419T3 (es) 2001-11-05 2006-02-16 Allergan, Inc. Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep-2.
AU2003211574A1 (en) 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2004089411A1 (ja) 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
US7323591B2 (en) * 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
JP2009541340A (ja) * 2006-06-20 2009-11-26 アラーガン インコーポレイテッド 治療用化合物

Also Published As

Publication number Publication date
DE602006013945D1 (de) 2010-06-10
TWI379696B (en) 2012-12-21
EP1846354A2 (de) 2007-10-24
US7635716B2 (en) 2009-12-22
NZ555945A (en) 2011-01-28
IL184025A (en) 2012-09-24
WO2006076370B1 (en) 2007-02-22
JP5060311B2 (ja) 2012-10-31
ES2343430T3 (es) 2010-07-30
US20080058414A1 (en) 2008-03-06
WO2006076370A3 (en) 2007-01-11
IL184025A0 (en) 2008-12-29
BRPI0605926A2 (pt) 2009-05-26
CN101102989B (zh) 2011-11-16
TW200714312A (en) 2007-04-16
MX2007008188A (es) 2007-08-07
AU2006205029A1 (en) 2006-07-20
JP2008526970A (ja) 2008-07-24
CA2593661A1 (en) 2006-07-20
ZA200704739B (en) 2009-10-28
KR101227808B1 (ko) 2013-01-30
AR052876A1 (es) 2007-04-11
AU2006205029B2 (en) 2012-09-06
DK1846354T3 (da) 2010-08-16
KR20070094919A (ko) 2007-09-27
CN101102989A (zh) 2008-01-09
HK1114601A1 (en) 2008-11-07
EP1846354B1 (de) 2010-04-28
WO2006076370A2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
EP2021352A4 (de) Behandlung von protein-missfaltung
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
IL184025A0 (en) Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EP2249765A4 (de) Dapson zur behandlung von rosascea
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
EP1876900A4 (de) Phosphoinositid-modulation zur behandlung von alzheimer-krankheit
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE502005002324D1 (de) Reaktor zur behandlung hochviskoser kunststoffschmelzen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE478668T1 (de) Pyrroloä1,2-aüimidazoldion zur behandlung von peripherer neurotoxizität durch chemotherapeutische mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties